Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

NCT00373373 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.

NCT NCT00373373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00373373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
Lead sponsor
University Hospital Muenster
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
July 31, 2009
Enrollment
200 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia